Formerly Xenomics, Inc., XNOM.PK

1. ‣Latest News

TrovaGene Inc., 11055 Flintkote Ave., Suite B, San Diego, CA 92121

June 21, 2010

TrovaGene Announces a Licensing Agreement with Skyline Diagnostics to Use Its NPM1 Technology for Laboratory Testing Services in Europe

» read more

April 15, 2010

TrovaGene Announces the Formation of Its Scientific Advisory Board

» read more

March 31, 2010

TrovaGene announces that its NPM1 technology is now part of LabCorp’s and InVivoScribe Technologies’ AML cancer testing services.

» read more   » download

March 8, 2010

TrovaGene, Inc. announces that Dr. Andreas Braun has joined the company as its Vice President and Chief Medical Officer.

» read more » download

March 2, 2010

TrovaGene, Inc. Announces Name and Ticker Symbol Change

TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM.PK) a developer of transrenal molecular diagnostics, announced today that it has changed its name from Xenomics, Inc. to TrovaGene, Inc. and re-domesticated its state of incorporation to Delaware from Florida. The Company’s stock symbol has been changed to TROV effective March 1, 2010.

» read more  » download

December 15, 2009

Xenomics, Inc., and its Subsidiary TrovaGene, Inc., Announce Italian Patent for NPM1 Testing for AML Patients

» read more

November 10, 2009

Xenomics Inc. and TrovaGene Inc. Announce HPV Patent Filing Based on Transrenal DNA Technology

» read more

TROV.PK

» News

» Conferences & Events